Skip to content
Hair Pipeline
← Back to the pipeline

Pyrilutamide

A topical androgen receptor blocker, aiming for finasteride's effect without the systemic exposure.

Phase 3TopicalAndrogen receptor

No public activity in over 18 months

Developed by
Kintor Pharmaceutical
Current phase
Phase 3

Large confirmatory trials. The last step before filing.

Indications
Androgenetic alopecia
Also known as
KX-826, KX826
Last public activity
October 2024
Record confidence
High

How it is meant to work

Binds the androgen receptor in the scalp so DHT can't act on the follicle. Because it is applied topically and designed to break down before reaching circulation, the intent is to avoid the systemic side effects that make oral antiandrogens a hard sell.

Why it matters

Furthest-advanced of the new topical antiandrogens. In March 2026 Kintor announced that the Phase III stage of its Chinese pivotal trial had met its primary endpoint. The thing to watch: earlier US results were mixed, and a drug that works in one trial population and not another usually has a dosing or delivery problem rather than a mechanism problem. A filing with China's NMPA is signalled for 2026; this register will move the row to filed when that is confirmed.

Development history

  1. Phase 2Phase 3

    First Phase 3 trial on record: NCT06126965 — Phase III Study of KX-826 With Adult Male Patients With AGA

    ClinicalTrials.gov ↗
  2. Phase 1Phase 2

    First Phase 2 trial on record: NCT05940506 — Phase II Study Evaluating the Efficacy and Safety of KX-826

    ClinicalTrials.gov ↗
  3. Phase 1

    First Phase 1 trial on record: NCT04984707 — Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT06622824Phase 2/3NOT YET RECRUITING

    To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia

    Suzhou Kintor Pharmaceutical Inc, · n=756 · October 2024

  • NCT05218642Phase 2COMPLETED

    To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

    Suzhou Kintor Pharmaceutical Inc, · n=123 · January 2022

  • NCT06126965Phase 3UNKNOWN

    Phase III Study of KX-826 With Adult Male Patients With AGA

    Suzhou Kintor Pharmaceutical Inc, · n=740 · December 2021

  • NCT06409650Phase 2COMPLETED

    To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia

    Suzhou Koshine Biomedica, Inc. · n=160 · November 2021

  • NCT05940506Phase 2COMPLETED

    Phase II Study Evaluating the Efficacy and Safety of KX-826

    Suzhou Kintor Pharmaceutical Inc, · n=120 · September 2020

  • NCT04502901Phase 1COMPLETED

    the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending

    Suzhou Kintor Pharmaceutical Inc, · n=40 · January 2020

  • NCT04984707Phase 1COMPLETED

    Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

    Suzhou Kintor Pharmaceutical Inc, · n=40 · January 2019

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources